Preferred Label : Bevacizumab/Liposomal Doxorubicin Regimen;
NCIt synonyms : Bevacizumab/Liposomal Doxorubicin; Liposomal Doxorubicin/Bevacizumab Regimen; Bevacizumab-Liposomal Doxorubicin; Doxil/Avastin; Bevacizumab/Pegylated Liposomal Doxorubicin; Pegylated Liposomal Doxorubicin/Bevacizumab; Avastin/Doxil;
NCIt related terms : Pegylated liposomal doxorubicin and Bevacizumab; Pegylated liposomal doxorubicin and Bevacizumab-equi; Pegylated liposomal doxorubicin and Bevacizumab-aybi; Pegylated liposomal doxorubicin and Bevacizumab-awwb; Pegylated liposomal doxorubicin and Bevacizumab-adcd; Pegylated liposomal doxorubicin and Bevacizumab-onbe; Pegylated liposomal doxorubicin and Bevacizumab-maly; Pegylated liposomal doxorubicin and Bevacizumab-bvzr;
NCIt definition : A regimen consisting of bevacizumab and liposomal doxorubicin that can be used for
the treatment of ovarian, fallopian tube, and primary peritoneal cancers.;
NCI Metathesaurus CUI : CL969524;
Codes from synonyms : 8189; 127606; 127162; 127384; 127532; 127236; 127458; 127310;
Origin ID : C160525;
UMLS CUI : C5205329;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
